4,052,467 Shares in Kenvue Inc. $KVUE Purchased by Sculptor Capital LP

Sculptor Capital LP acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,052,467 shares of the company’s stock, valued at approximately $77,443,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Physician Wealth Advisors Inc. increased its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Elyxium Wealth LLC bought a new stake in shares of Kenvue in the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. acquired a new stake in Kenvue during the second quarter worth approximately $26,000. MV Capital Management Inc. acquired a new stake in Kenvue during the fourth quarter worth approximately $28,000. Finally, CoreCap Advisors LLC increased its stake in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.4%

NYSE KVUE opened at $19.34 on Wednesday. The business has a fifty day moving average price of $19.10 and a two-hundred day moving average price of $18.22. The stock has a market capitalization of $37.16 billion, a PE ratio of 22.24, a PEG ratio of 1.39 and a beta of 0.47. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.40. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Analyst Ratings Changes

KVUE has been the subject of several analyst reports. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group reduced their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays boosted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.